CLINICAL_TRIALS
trial_result
· 2026-03-02
Clinical Trial Update: Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients [Phase 2]
Summary
An open-label extension Phase 2 trial evaluating GLM101 in PMM2-CDG patients is currently enrolling by invitation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Glycomine, Inc. | Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 2 | Status: ENROLLING_BY_INVITATION